To evaluate the effectiveness of low-dose radiation therapy (LDRT) and FOLFIRIbevacizumab (FOLFIRI-B) combination in metastatic colorectal cancer. Methods: The primary objective of the study is to raise the clinical complete response (CR) rate from 5% to 25%. Secondary objectives include toxicity and progression-free survival. Patients underwent 12 FOLFIRIB cycles plus two daily LDRT (20 cGy/6-hour interval) on the first and second days of each cycle. Results: CR and toxicity of 10 patients are reported. Considering irradiated sites, 10/10 patients had clinical partial response (PR) (7/10) or CR (3/10). Three clinical PR patients subsequently underwent surgery and reported a pathological CR in the irradiated sites. Grade 3–4 toxicities rate was 30%. With a median followup of 29 months (range: 12–49 months), 2/10 progression of disease in irradiated sites and 3/5 in nonirradiated sites were observed. Conclusions: The very high response rate requires urgent verification in a larger patient series.
FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: Preliminary results of a phase I–II study / Morganti, A.G; Mignogna, S; Caravatta, L; Deodato, F; Macchia, G.; Plantamura, N.M; Massaccesi, M.; Picardi, V; Cilla, S.; Valentini, V. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - ELETTRONICO. - 26:6(2014), pp. 353-358. [10.1179/1973947813Y.0000000163]
FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: Preliminary results of a phase I–II study
MORGANTI, ALESSIO GIUSEPPE;
2014
Abstract
To evaluate the effectiveness of low-dose radiation therapy (LDRT) and FOLFIRIbevacizumab (FOLFIRI-B) combination in metastatic colorectal cancer. Methods: The primary objective of the study is to raise the clinical complete response (CR) rate from 5% to 25%. Secondary objectives include toxicity and progression-free survival. Patients underwent 12 FOLFIRIB cycles plus two daily LDRT (20 cGy/6-hour interval) on the first and second days of each cycle. Results: CR and toxicity of 10 patients are reported. Considering irradiated sites, 10/10 patients had clinical partial response (PR) (7/10) or CR (3/10). Three clinical PR patients subsequently underwent surgery and reported a pathological CR in the irradiated sites. Grade 3–4 toxicities rate was 30%. With a median followup of 29 months (range: 12–49 months), 2/10 progression of disease in irradiated sites and 3/5 in nonirradiated sites were observed. Conclusions: The very high response rate requires urgent verification in a larger patient series.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
